Site-specific analysis of advanced glycation end products in plasma proteins of type 2 diabetes mellitus patients

被引:29
|
作者
Greifenhagen, Uta [1 ,2 ]
Frolov, Andrej [1 ,3 ]
Blueher, Matthias [4 ]
Hoffmann, Ralf [1 ,2 ]
机构
[1] Univ Leipzig, Inst Bioanalyt Chem, Fac Chem & Mineral, Deutsch Pl 5, D-04103 Leipzig, Germany
[2] Univ Leipzig, Ctr Biotechnol & Biomed BBZ, Deutsch Pl 5, D-04103 Leipzig, Germany
[3] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Germany
[4] Univ Leipzig, Dept Med, Endocrinol, Liebigstr 20, D-04103 Leipzig, Germany
关键词
Advanced glycation end product (AGE); Mass spectrometry; Non-enzymatic modification; Posttranslational modification (PTM); Proteomics; Type 2 diabetes mellitus (T2DM); MOLECULAR-BASIS; AGE; IDENTIFICATION; DEGRADATION; METHYLGLYOXAL; ENDPRODUCTS; PEPTIDES; ACCUMULATION; LENS;
D O I
10.1007/s00216-016-9651-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Advanced glycation end products (AGEs) are posttranslational modifications formed non-enzymatically from the reaction of carbohydrates and their degradation products with proteins. Accumulation of AGEs is associated with the progression of severe diabetic complications, for example, and elevated tissue levels of AGEs might even predict these pathologies. As AGE formation is often site-specific, mapping of these modification sites may reveal more sensitive and specific markers than the global tissue level. Here, 42 AGE modifications were identified in a bottom-up proteomic approach by tandem mass spectrometry, which corresponded to 36 sites in 22 high to medium abundant proteins in individual plasma samples obtained from type 2 diabetes mellitus (T2DM) patients with long disease duration (> 10 years). Major modifications were glarg (11 modification sites) and carboxymethylation (5) of arginine and formylation (8), acetylation (7), and carboxymethylation (7) of lysine residues. Relative quantification of these sites in plasma samples obtained from normoglycemic individuals (n = 47) and patients with T2DM being newly diagnosed (n = 47) or of medium (2-5 years, n = 20) and long disease duration (> 10 years, n = 20) did not reveal any significant differences.
引用
收藏
页码:5557 / 5566
页数:10
相关论文
共 50 条
  • [1] Site-specific analysis of advanced glycation end products in plasma proteins of type 2 diabetes mellitus patients
    Uta Greifenhagen
    Andrej Frolov
    Matthias Blüher
    Ralf Hoffmann
    Analytical and Bioanalytical Chemistry, 2016, 408 : 5557 - 5566
  • [2] Plasma Proteins Modified by Advanced Glycation End Products (AGEs) Reveal Site-specific Susceptibilities to Glycemic Control in Patients with Type 2 Diabetes
    Greifenhagen, Uta
    Frolov, Andrej
    Blueher, Matthias
    Hoffmann, Ralf
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (18) : 9610 - 9616
  • [3] Assessment of Pentosidine as a Marker for Advanced Glycation End Products in Type 2 Diabetes Mellitus Patients
    Jaishankar, Sarath Kumar Jaganathan
    Murali, Amrutha
    Marzooka, Amrin
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2020, 14 (02)
  • [4] Role of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitus
    Sanchis, Pilar
    Rivera, Rosmeri
    Fortuny, Regina
    Rio, Carlos
    Mas-Gelabert, Miguel
    Gonzalez-Freire, Marta
    Grases, Felix
    Masmiquel, Luis
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06) : 1 - 16
  • [5] Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
    Nowotny, Kerstin
    Jung, Tobias
    Hoehn, Annika
    Weber, Daniela
    Grune, Tilman
    BIOMOLECULES, 2015, 5 (01): : 194 - 222
  • [6] Intra-articular site-specific distribution of advanced glycation end products in the shoulder of patients with diabetes mellitus having rotator cuff tears
    Tatsuo Kato
    Issei Shinohara
    Yutaka Mifune
    Atsuyuki Inui
    Hanako Nishimoto
    Tomoya Yoshikawa
    Takahiro Furukawa
    Shuya Tanaka
    Masaya Kusunose
    Yuichi Hoshino
    Takehiko Matsushita
    Ryosuke Kuroda
    Molecular Biology Reports, 2023, 50 : 10339 - 10349
  • [7] Intra-articular site-specific distribution of advanced glycation end products in the shoulder of patients with diabetes mellitus having rotator cuff tears
    Kato, Tatsuo
    Shinohara, Issei
    Mifune, Yutaka
    Inui, Atsuyuki
    Nishimoto, Hanako
    Yoshikawa, Tomoya
    Furukawa, Takahiro
    Tanaka, Shuya
    Kusunose, Masaya
    Hoshino, Yuichi
    Matsushita, Takehiko
    Kuroda, Ryosuke
    MOLECULAR BIOLOGY REPORTS, 2023, 50 (12) : 10339 - 10349
  • [8] Antibodies against advanced glycation end products in patients with type 1 diabetes mellitus
    González, M
    Paquién, C
    Asenjo, S
    Gleisner, A
    Kirsten, L
    Bustamante, M
    REVISTA MEDICA DE CHILE, 2001, 129 (02) : 141 - 148
  • [9] Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes
    Nakamura, N
    Yamazaki, K
    Satoh, A
    Urakaze, M
    Kobayashi, M
    Yamabe, H
    Osawa, H
    Shirato, K
    Sugawara, T
    Nakamura, M
    Tamura, M
    Okumura, K
    IN VIVO, 2003, 17 (02): : 177 - 180
  • [10] Advanced Glycation End Products in the Development of Ischemic and Dilated Cardiomyopathy in Patients With Diabetes Mellitus Type 2
    Nozynski, J.
    Zakliczynski, M.
    Konecka-Mrowka, D.
    Nikiel, B.
    Mlynarczyk-Liszka, J.
    Zembala-Nozyriska, E.
    Lange, D.
    Maruszewski, M.
    Zembala, M.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (01) : 99 - 104